BIOE reaches strategic cooperation with Swisse to restart the journey of the US stock market
At the time when the global health product industry is surging, the senior executive delegation from Bio Essence Corp (stock code: BIOE) recently went to Australia for a strategic meeting with the world-renowned health product brand Swisse. The two sides reached a consensus on this major cooperation in the health product field, marking a solid step for BIOE in its internationalization strategy layout. This cooperation will not only bring consumers higher quality and more innovative health products, but also herald a new round of challenges and opportunities for BIOE in Capital Markets.
Deep cooperation with Swisse to build a healthy new ecology
According to people close to BIOE, this strategic cooperation with Swisse covers multiple cutting-edge directions in the field of health products, including but not limited to raw material procurement, technology innovation sharing, and marketing activity strategies. Both parties will fully utilize their respective advantageous resources in research and development, production, sales, etc., jointly explore the infinite possibilities of the health product market, and provide consumers with more scientific, safe, and efficient health solutions.
As a leader in the global health products industry, Swisse’s brand influence and market position are self-evident, “BIOE executives once told insiders.” We are very honored to work with such an outstanding enterprise to jointly promote innovation and development in the health products industry. We believe that through close cooperation between the two parties, we can lead the entire industry to a new height.
Rising from setbacks, BIOE Capital Markets embarks on a new journey
Looking back at BIOE’s Capital Markets history, the attempt to transfer the US stock OTC market in July of this year was undoubtedly an important milestone in its development. However, due to insufficient estimation of market environment changes and the complexity of internal preparation work, the transfer ultimately failed.
After the failed transfer, BIOE conducted a profound self-analysis internally, quickly adjusted its strategic direction, strengthened internal management, and optimized its business structure. At the same time, the company actively sought external cooperation opportunities in order to inject new vitality into the company’s future development by introducing new strategic partners and resources.
According to insiders, BIOE will soon reach a strategic cooperation with the globally renowned consulting firm AlixPartners. AlixPartners is renowned for its profound industry insights and rich consulting experience in helping enterprises optimize operations and develop strategic transformation plans. In this cooperation, the two parties will carry out in-depth cooperation on optimizing corporate governance structure, innovating business models, and expanding market strategies, jointly promoting BIOE’s leapfrog development and laying a solid foundation for future impact on the US stock market.
Successive cooperation with Swisse and Alibo undoubtedly injects strong impetus into the future development of BIOE. On the one hand, through strategic cooperation with Swisse, BIOE will have direct access to world-class health product research and development technology and market resources, which helps to enhance the company’s core competitiveness and accelerate the internationalization process. On the other hand, cooperation with Alibo provides professional consulting support and strategic guidance for the company, which helps the company to more accurately grasp market trends and formulate strategic paths that are in line with its own development.
The series of cooperations send a clear signal to the outside world: BIOE has not been discouraged by temporary setbacks, but has actively sought new development opportunities with a more determined and open attitude. With the gradual implementation and in-depth promotion of these cooperative projects, we believe that BIOE will achieve higher levels of success in the field of health products with its unique innovation ability and keen market insight, and also bring more substantial returns to investors.